Noxopharm Ltd (ASX:NOX), an Australian biotech company, listed on the ASX today after raising $6 million in an over-subscribed IPO.
The clinic-ready company is focused on commencing the first human clinical trial for its drug, NOX66.
The purpose of NOX66 is to eliminate the ability of a cancer cell to develop and maintain its drug-resistance mechanisms, something that leads to many cancer patients eventually running out of treatment options.
Graham Kelly, CEO, held various senior roles for nearly 20 years at Novogen, a $1+ billion company. Novogen attempted to develop an anti-cancer drug targeting a similar market.
At 3:00PM Sydney time, over 5 million Noxopharm shares had been traded on the ASX.
Shares issued under the IPO were priced at $0.20 and shares have traded between $0.18 and $0.20 today.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.
